Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria

Ariel H. Achtman, Sandra Pilat, Charity W. Law, David J. Lynn, Laure Janot, Matt L. Mayer, Shuhua Ma, Jason Kindrachuk, B. Brett Finlay, Fiona S.L. Brinkman, Gordon K. Smyth, Robert E.W. Hancock, Louis Schofield

Research output: Contribution to journalArticlepeer-review

85 Citations (Scopus)


Case fatality rates for severe malaria remain high even in the best clinical settings because antimalarial drugs act against the parasite without alleviating life-threatening inflammation. We assessed the potential for host-directed therapy of severe malaria of a new class of anti-inflammatory drugs, the innate defense regulator (IDR) peptides, based on host defense peptides. The Plasmodium berghei ANKA model of experimental cerebral malaria was adapted to use as a preclinical screen by combining late-stage intervention in established infections with advanced bioinformatic analysis of early transcriptional changes in co-regulated gene sets. Coadministration of IDR-1018 with standard first-line antimalarials increased survival of infected mice while down-regulating key inflammatory networks associated with fatality. Thus, IDR peptides provided host-directed adjunctive therapy for severe disease in combination with antimalarial treatment.

Original languageEnglish
Article number135ra64
JournalScience Translational Medicine
Issue number135
Publication statusPublished or Issued - 23 May 2012
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Cite this